These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11249591)

  • 41. Emerging mechanisms of fluoroquinolone resistance.
    Hooper DC
    Emerg Infect Dis; 2001; 7(2):337-41. PubMed ID: 11294736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of Azaindole Ureas as a Novel Class of Bacterial Gyrase B Inhibitors.
    Zhang J; Yang Q; Cross JB; Romero JA; Poutsiaka KM; Epie F; Bevan D; Wang B; Zhang Y; Chavan A; Zhang X; Moy T; Daniel A; Nguyen K; Chamberlain B; Carter N; Shotwell J; Silverman J; Metcalf CA; Ryan D; Lippa B; Dolle RE
    J Med Chem; 2015 Nov; 58(21):8503-12. PubMed ID: 26460684
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel antimicrobial agents against multi-drug-resistant gram-positive bacteria: an overview.
    Giannakaki V; Miyakis S
    Recent Pat Antiinfect Drug Discov; 2012 Dec; 7(3):182-8. PubMed ID: 23016758
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.
    Neu HC
    Drugs; 1993; 45 Suppl 3():54-8. PubMed ID: 7689452
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In Vitro and in Vivo Evaluation of Membrane-Active Flavone Amphiphiles: Semisynthetic Kaempferol-Derived Antimicrobials against Drug-Resistant Gram-Positive Bacteria.
    Lin S; Li H; Tao Y; Liu J; Yuan W; Chen Y; Liu Y; Liu S
    J Med Chem; 2020 Jun; 63(11):5797-5815. PubMed ID: 32400157
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluoroquinolones: structure and target sites.
    Higgins PG; Fluit AC; Schmitz FJ
    Curr Drug Targets; 2003 Feb; 4(2):181-90. PubMed ID: 12558069
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impermeability to quinolones in gram-positive and gram-negative bacteria.
    Bryan LE; Bedard J
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):232-9. PubMed ID: 1864283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram positive activity and improved safety profile.
    Surivet JP; Zumbrunn C; Rueedi G; Bur D; Bruyère T; Locher H; Ritz D; Seiler P; Kohl C; Ertel EA; Hess P; Gauvin JC; Mirre A; Kaegi V; Dos Santos M; Kraemer S; Gaertner M; Delers J; Enderlin-Paput M; Weiss M; Sube R; Hadana H; Keck W; Hubschwerlen C
    J Med Chem; 2015 Jan; 58(2):927-42. PubMed ID: 25494934
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.
    Poole K
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2595-9. PubMed ID: 10991829
    [No Abstract]   [Full Text] [Related]  

  • 50. Impact of the fluoroquinolones on gastrointestinal flora.
    Korten V; Murray BE
    Drugs; 1993; 45 Suppl 3():125-33. PubMed ID: 7689443
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Avoiding fluoroquinolone resistance. Strategies for primary care practice.
    Stratton CW
    Postgrad Med; 1997 Mar; 101(3):247-50, 255. PubMed ID: 9074562
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluoroquinolones in animal health.
    Brown SA
    J Vet Pharmacol Ther; 1996 Feb; 19(1):1-14. PubMed ID: 8992019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Concentrations preventing resistance mutations against fluoroquinolones].
    Dubreuil L
    Presse Med; 2002 Nov; 31(38):1807-9. PubMed ID: 12497723
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New fluoroquinolones and treatment of acute sinusitis].
    Gehanno P; Trémolières F
    Presse Med; 1999 Sep; 28(25):1365. PubMed ID: 10506868
    [No Abstract]   [Full Text] [Related]  

  • 55. Premafloxacin: a projected veterinary use fluoro-quinolone with significant activity against multi-resistant gram-positive human pathogens.
    Zerva L; Marshall SA; Jones RN
    J Antimicrob Chemother; 1996 Oct; 38(4):742-4. PubMed ID: 8937972
    [No Abstract]   [Full Text] [Related]  

  • 56. Biological activity and synthetic metodologies for the preparation of fluoroquinolones, a class of potent antibacterial agents.
    Da Silva AD; De Almeida MV; De Souza MV; Couri MR
    Curr Med Chem; 2003 Jan; 10(1):21-39. PubMed ID: 12570719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The fluoroquinolones: how long will their utility last?
    Bakken JS
    Scand J Infect Dis; 2004; 36(2):85-92. PubMed ID: 15061660
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nybomycin inhibits both types of
    Shiriaev DI; Sofronova AA; Berdnikovich EA; Lukianov DA; Komarova ES; Marina VI; Zakalyukina YV; Biryukov MV; Maviza TP; Ivanenkov YA; Sergiev PV; Osterman IA; Dontsova OA
    Antimicrob Agents Chemother; 2023 May; 95(5):. PubMed ID: 33593838
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Latest news on fluoroquinolones].
    Bergogne-Bérézin E
    Presse Med; 2002 Nov; 31(38):1805-6. PubMed ID: 12497722
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fluoroquinolone treatment of skin and skin structure infections.
    Karchmer AW
    Drugs; 1999; 58 Suppl 2():82-4. PubMed ID: 10553712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.